First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
This clearance allows the company to initiate a clinical trial for patients with an ileal pouch-anal anastomosis
The plant at Raleigh, North Carolina, USA owned by Aurolife Pharma has received an establishment inspection report (EIR)
The unit has filed 2 Derma products and 1 MDI product.
The company continues to cooperate with the US FDA and is committed to undertake all necessary steps required to address their observations at the earliest
First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization
A total of five observations for Goa and 17 for Monroe
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
The expansion positions Cambrex with the largest and most advanced API facility in the United States
The RTP manufacturing facility will support the company's clinical studies and early commercial launch in North America and Europe
Subscribe To Our Newsletter & Stay Updated
